News

Company Announces Coronavirus Vaccine Development Is Way Ahead of Schedule

Combined Shape

Pharmaceutical giant Johnson & Johnson announced Wednesday that its early stage human trial for a potential coronavirus vaccine will start in July, two months ahead of schedule.

The human clinical trial was initially scheduled to begin in September but is now expected to start in the second half of July, according to a news release from the company.

“Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant,” Paul Stoffels, vice chairman of the executive committee and chief scientific officer, said in a statement.

“Simultaneously, we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities.”

Trending:
Watch: Biden Stumbles, Struggles to Speak for 41 Seconds Straight

He added, “Our goal is to ensure we can deliver a vaccine to the world and protect people everywhere from this pandemic.”

The pharmaceutical company began developing a vaccine for COVID-19 in January by using the same technology it used to make its experimental Ebola vaccine, CNBC reported.

Development involves combining genetic material from the novel coronavirus with a modified adenovirus, which causes the common cold.

The early stage human trial will test the vaccine on 1,045 healthy adults between 18 and 55 years old and healthy adults above 65 years of age.

Johnson & Johnson is one pharmaceutical company that has partnered with the U.S. government to produce up to 1 billion doses of a coronavirus vaccine for use around the world throughout 2021.

The company is working directly with the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services.

Forbes reported that Johnson & Johnson entered into the $1 billion deal with the federal government to develop the vaccine in March.

Under the terms of the agreement, the government will pay $456 million and Johnson & Johnson will cover the rest of the cost for the vaccine’s research, development and testing.

Related:
Biden Claims Republicans Are in the Midst of a 'Mini-Revolution'

As of June 2, there were 124 possible COVID-19 vaccines under development, according to the World Health Organization.

Moderna Inc. announced promising results at the end of May regarding early testing of its COVID-19 vaccine.

The company said the vaccine appeared safe and able to ward off the virus, though detailed results have yet to be published.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, expressed “cautious optimism” regarding the Moderna results.

“Having looked at the data myself, it is really quite promising,” Fauci told NPR.

“The vaccine induced what we call neutralizing antibodies, as opposed to just binding antibodies, and neutralizing antibodies are antibodies that actually can block the virus,” he said.

As of Thursday, there were over 7.4 million cases of COVID-19 worldwide and 418,392 deaths, according to data from Johns Hopkins.

Truth and Accuracy

Submit a Correction →






We are committed to truth and accuracy in all of our journalism. Read our editorial standards.

Tags:
, , ,
Erin Coates was an editor for The Western Journal for over two years before becoming a news writer. A University of Oregon graduate, Erin has conducted research in data journalism and contributed to various publications as a writer and editor.
Erin Coates was an editor for The Western Journal for over two years before becoming a news writer. She grew up in San Diego, California, proceeding to attend the University of Oregon and graduate with honors holding a degree in journalism. During her time in Oregon, Erin was an associate editor for Ethos Magazine and a freelance writer for Eugene Magazine. She has conducted research in data journalism, which has been published in the book “Data Journalism: Past, Present and Future.” Erin is an avid runner with a heart for encouraging young girls and has served as a coach for the organization Girls on the Run. As a writer and editor, Erin strives to promote social dialogue and tell the story of those around her.
Birthplace
Tucson, Arizona
Nationality
American
Honors/Awards
Graduated with Honors
Education
Bachelor of Arts in Journalism, University of Oregon
Books Written
Contributor for Data Journalism: Past, Present and Future
Location
Prescott, Arizona
Languages Spoken
English, French
Topics of Expertise
Politics, Health, Entertainment, Faith




Conversation